The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Preclinical Properties of 18F-AV-45: A PET Agent for Aβ Plaques in the Brain
Open accessAbstract
UNLABELLED: beta-amyloid plaques (Abeta plaques) in the brain, containing predominantly fibrillary Abeta peptide aggregates, represent a defining pathologic feature of Alzheimer disease (AD). Imaging agents targeting the Abeta plaques in the living human brain are potentially valuable as biomarkers of pathogenesis processes in AD. (E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methyl benzenamine ((18)F-AV-45) is such as an agent currently in phase III clinical studies for PET of Abeta plaques in the brain. METHODS: In vitro binding of (18)F-AV-45 to Abeta plaques in the postmortem AD brain tissue was evaluated by in vitro binding assay and autoradiography. In vivo biodistribution of (18)F-AV-45 in mice and ex vivo autoradiography of AD transgenic mice (APPswe/PSEN1) with Abeta aggregates in the brain were performed. Small-animal PET of a monkey brain after an intravenous injection of (18)F-AV-45 was evaluated. RESULTS: (18)F-AV-45 displayed a high binding affinity and specificity to Abeta plaques (K(d), 3.72 +/- 0.30 nM). In vitro autoradiography of postmortem human brain sections showed substantial plaque labeling in AD brains and not in the control brains. Initial high brain uptake and rapid washout from the brain of healthy mice and monkey were observed. Metabolites produced in the blood of healthy mice after an intravenous injection were identified. (18)F-AV-45 displayed excellent binding affinity to Abeta plaques in the AD brain by ex vivo autoradiography in transgenic AD model mice. The results lend support that (18)F-AV-45 may be a useful PET agent for detecting Abeta plaques in the living human brain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents
Mathis, C. A., Wang, Y., Holt, D. P., Huang, G.-F., Debnath, M. L., & Klunk, W. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030026b · Cited by 979
Mandelkow, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01368-3 · Cited by 953
Burns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b158 · Cited by 859
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
Small, G. W., Kepe, V., Ercoli, L. M., Siddarth, P., Bookheimer, S. Y., Miller, K. J., Lavretsky, H., Burggren, A. C., Cole, G. M., Vinters, H. V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054625 · Cited by 738
Rowe, C. C., Ackerman, U., Browne, W., Mulligan, R., Pike, K. L., O'Keefe, G., Tochon-Danguy, H., Chan, G., Berlangieri, S. U., Jones, G., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70001-2 · Cited by 671
Self-citation100 Years and Counting: Prospects for Defeating Alzheimer's Disease
Roberson, E. D., & Mucke, L. (2006) · Science · doi:10.1126/science.1132813 · Cited by 550
Diagnostic Criteria for Neuropathologic Assessment of Alzheimer’s Disease
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00062-6 · Cited by 410
Hippocampal atrophy rates in Alzheimer disease: Added value over whole brain volume measures
Henneman, W. J. P., Sluimer, J. D., Barnes, J., van der Flier, W. M., Sluimer, I. C., Fox, N. C., Scheltens, P., Vrenken, H., & Barkhof, F. (2009) · Neurology · doi:10.1212/01.wnl.0000344568.09360.31 · Cited by 350
In-Vivo Imaging of Alzheimer Disease -Amyloid With [11C]SB-13 PET
Verhoeff, N. P. L. G. (2004) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.12.6.584 · Cited by 317
Silverman, D. H. S. (2004) · PubMed · Cited by 276
F-18 Polyethyleneglycol stilbenes as PET imaging agents targeting Aβ aggregates in the brain
Zhang, W., Oya, S., Kung, M.-P., Hou, C., Maier, D. L., & Kung, H. F. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.06.001 · Cited by 243
Self-citationHas the Amyloid Cascade Hypothesis for Alzheimers Disease been Proved?
Hardy, J. (2006) · Current Alzheimer Research · doi:10.2174/156720506775697098 · Cited by 241
Burns, A., & Iliffe, S. (2009) · BMJ · doi:10.1136/bmj.b75 · Cited by 230
In vivo amyloid imaging with PET in frontotemporal dementia
Engler, H., Santillo, A. F., Wang, S. X., Lindau, M., Savitcheva, I., Nordberg, A., Lannfelt, L., Långström, B., & Kilander, L. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0523-1 · Cited by 214
11C-labeled stilbene derivatives as Aβ-aggregate-specific PET imaging agents for Alzheimer’s disease
Ono, M., Wilson, A., Nobrega, J., Westaway, D., Verhoeff, P., Zhuang, Z.-P., Kung, M.-P., & Kung, H. F. (2003) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(03)00049-0 · Cited by 209
Self-citationIMPY: an improved thioflavin-T derivative for in vivo labeling of β-amyloid plaques
Kung, M.-P., Hou, C., Zhuang, Z.-P., Zhang, B., Skovronsky, D., Trojanowski, J. Q., Lee, V. M.-Y., & Kung, H. F. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03436-4 · Cited by 196
Self-citationRecent developments in Alzheimer's disease therapeutics
Rafii, M. S., & Aisen, P. S. (2009) · BMC Medicine · doi:10.1186/1741-7015-7-7 · Cited by 187
Novel Stilbenes as Probes for Amyloid Plaques
Kung, H. F., Lee, C.-W., Zhuang, Z.-P., Kung, M.-P., Hou, C., & Plössl, K. (2001) · Journal of the American Chemical Society · doi:10.1021/ja0167147 · Cited by 180
Self-citationFactors associated with resistance to dementia despite high Alzheimer disease pathology
Erten‐Lyons, D., Woltjer, R. L., Dodge, H. H., Nixon, R. A., Vorobik, R., Calvert, J. F., Leahy, M., Montine, T. J., & Kaye, J. A. (2009) · Neurology · doi:10.1212/01.wnl.0000341273.18141.64 · Cited by 166
F-18 Stilbenes as PET Imaging Agents for Detecting β-Amyloid Plaques in the Brain
Zhang, W., Oya, S., Kung, M., Hou, C., Maier, D. L., & Kung, H. F. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050166g · Cited by 151
Self-citationNewberg, A. B., Wintering, N., Plößl, K., Hochold, J., Stabin, M. G., Watson, M., Skovronsky, D., Clark, C. M., Kung, M., & Kung, H. F. (2006) · PubMed · Cited by 143
Self-citationRadioligand Development for PET Imaging of β-Amyloid (Aβ)-Current Status
Cai, L., Innis, R. B., & Pike, V. W. (2006) · Current Medicinal Chemistry · doi:10.2174/092986707779313471 · Cited by 142
Impact of amyloid imaging on drug development in Alzheimer's disease
Mathis, C. A., Lopresti, B. J., & Klunk, W. E. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.06.015 · Cited by 140
Detection of Alzheimer Pathology In Vivo Using Both 11C-PIB and 18F-FDDNP PET
Tolboom, N., Yaqub, M. M., van der Flier, W. M., Boellaard, R., Luurtsema, G., Windhorst, A. D., Barkhof, F., Scheltens, P., Lammertsma, A. A., & van Berckel, B. N. M. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.056499 · Cited by 137
18F-labeled styrylpyridines as PET agents for amyloid plaque imaging
Zhang, W., Kung, M., Oya, S., Hou, C., & Kung, H. F. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.10.003 · Cited by 111
Self-citationThe future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation
Klunk, W. E., & Mathis, C. A. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283168e1a · Cited by 99
Svedberg, M. M., Hall, H., Hellström‐Lindahl, E., Estrada, S., Guan, Z.-Z., Nordberg, A. K., & Långström, B. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.016 · Cited by 93
Kung, M., Hou, C., Zhuang, Z., Cross, A. J., Maier, D. L., & Kung, H. (2004) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-004-1487-z · Cited by 77
Self-citationNovel Radioiodinated Aurones as Probes for SPECT Imaging of β-Amyloid Plaques in the Brain
Maya, Y., Ono, M., Watanabe, H., Haratake, M., Saji, H., & Nakayama, M. (2008) · Bioconjugate Chemistry · doi:10.1021/bc8003292 · Cited by 73
Henriksen, G., Yousefi, B. H., Drzezga, A. E., & Wester, H. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0705-x · Cited by 71
Imaging Alzheimer's disease: clinical applications
Minoshima, S. (2003) · Neuroimaging Clinics of North America · doi:10.1016/s1052-5149(03)00099-6 · Cited by 69
Imaging Technology for Neurodegenerative Diseases
Mathis, C. A., Klunk, W. E., Price, J. C., & DeKosky, S. T. (2005) · Archives of Neurology · doi:10.1001/archneur.62.2.196 · Cited by 68
Fluoro-pegylated (FPEG) Imaging Agents Targeting Aβ Aggregates
Stephenson, K. A., Chandra, R., Zhuang, Z., Hou, C., Oya, S., Kung, M., & Kung, H. F. (2006) · Bioconjugate Chemistry · doi:10.1021/bc060239q · Cited by 66
Self-citationNovel Styrylpyridines as Probes for SPECT Imaging of Amyloid Plaques
Qü, W., Kung, M., Hou, C., Benedum, T. E., & Kung, H. F. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070025+ · Cited by 51
Self-citationSynthesis and β-amyloid binding properties of rhenium 2-phenylbenzothiazoles
Lin, K., Debnath, M. L., Mathis, C. A., & Klunk, W. E. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.02.096 · Cited by 43
Dissecting Molecular Mechanisms in the Living Brain of Dementia Patients
Barrio, J. R., Satyamurthy, N., Huang, S., Petrič, A., Small, G. W., & Kepe, V. (2009) · Accounts of Chemical Research · doi:10.1021/ar800189x · Cited by 41
Development and Evaluation of Iodinated Tracers Targeting Amyloid Plaques for SPECT Imaging
Kung, M., Zhuang, Z., Hou, C., & Kung, H. F. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:1:049 · Cited by 20
Self-citation
Cited by
Applications of Fluorine in Medicinal Chemistry
Gillis, E. P., Eastman, K. J., Hill, M. D., Donnelly, D. J., & Meanwell, N. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00258 · Cited by 3,618
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684
“(E)-4-(2-(6-(2(2-(2-18F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)N-methyl benzenamine (18F-AV-45 or flobetapir F 18) was selected from a series of agents as the tracer with the optimum kinetics and selectivity for Ab plaques (11).”
MethodSelf-citation[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease
Xia, C., Arteaga, J., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., Mocharla, V. P., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.008 · Cited by 605
Self-citationThe Alzheimer's Disease Neuroimaging Initiative positron emission tomography core
Jagust, W. J., Bandy, D., Chen, K., Foster, N. L., Landau, S. M., Mathis, C. A., Price, J. C., Reiman, E. M., Skovronsky, D., Koeppe, R. A., et al. (2010) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.03.003 · Cited by 533
Self-citation
Metadata
- Authors
- Choi, S. R., Golding, G., Zhuang, Z., Zhang, W., Lim, N., Hefti, F., Benedum, T. E., Kilbourn, M. R., Skovronsky, D., & Kung, H. F.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2009-10-16
- Volume
- 50
- Issue
- 11
- Pages
- 1887-1894
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2137632876
- Cited by
- 431
- References
- 38
- FWCI
- 24.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.